Literature DB >> 22249919

C5a receptor (CD88) inhibition improves hypothermia-induced neuroprotection in an in vitro ischemic model.

John Thundyil1, Dale Pavlovski, Yu-Hsuan Hsieh, Mathias Gelderblom, Tim Magnus, David P Fairlie, Thiruma V Arumugam.   

Abstract

The concept of 'salvageble penumbra' has prompted both scientists and physicians to explore various neuroprotective approaches that could be beneficial during stroke therapy. Unfortunately, most of them have proved ineffective in targeting multiple cellular death cascades incited within the ischemic penumbra. Hypothermia has been shown to be capable of addressing this problem to some extent. Although many studies have shown that hypothermia targets several cellular processes, its effects on innate immune receptor-mediated apoptotic death still remain unclear. Moreover, whether inhibiting the signaling of innate immune receptors like complement anaphylatoxin C5a receptor (CD88) plays a role in this hypothermic neuroprotection still need to be deciphered. Using various types of ischemic insults in different neuronal cells, we confirm that hypothermia does indeed attenuate apoptotic neuronal cell death in vitro and this effect can be further enhanced by pharmacologically blocking or knocking out CD88. Thus, our study raises a promising therapeutic possibility of adding CD88 antagonists along with hypothermia to improve stroke outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249919     DOI: 10.1007/s12017-012-8167-0

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  40 in total

1.  Neuronal differentiation triggered by blocking cell proliferation.

Authors:  P LoPresti; W Poluha; D K Poluha; E Drinkwater; A H Ross
Journal:  Cell Growth Differ       Date:  1992-09

Review 2.  Neurodegenerative disorders and ischemic brain diseases.

Authors:  M P Mattson; W Duan; W A Pedersen; C Culmsee
Journal:  Apoptosis       Date:  2001 Feb-Apr       Impact factor: 4.677

3.  1,026 experimental treatments in acute stroke.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; Laura L Horky; Bart H van der Worp; David W Howells
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding.

Authors:  Anne-Marie Scola; Adrian Higginbottom; Lynda J Partridge; Robert C Reid; Trent Woodruff; Stephen M Taylor; David P Fairlie; Peter N Monk
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

5.  Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death.

Authors:  Thiruma V Arumugam; Sung-Chun Tang; Justin D Lathia; Aiwu Cheng; Mohamed R Mughal; Srinivasulu Chigurupati; Tim Magnus; Sic L Chan; Dong-Gyu Jo; Xin Ouyang; David P Fairlie; Daniel N Granger; Alexander Vortmeyer; Milan Basta; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

Review 6.  Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis.

Authors:  H Bart van der Worp; Emily S Sena; Geoffrey A Donnan; David W Howells; Malcolm R Macleod
Journal:  Brain       Date:  2007-05-03       Impact factor: 13.501

7.  C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2.

Authors:  Lambertus H C Van Lith; Julia Oosterom; Andrea Van Elsas; Guido J R Zaman
Journal:  J Biomol Screen       Date:  2009-07-29

8.  Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials.

Authors:  Jeffrey L Saver; Gregory W Albers; Billy Dunn; Karen C Johnston; Marc Fisher
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

Review 9.  Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.

Authors:  David J Gladstone; Sandra E Black; Antoine M Hakim
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

Review 10.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more
  6 in total

1.  Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice.

Authors:  Q Guo; J Cheng; J Zhang; B Su; C Bian; S Lin; C Zhong
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

2.  Exogenous inter-α inhibitor proteins prevent cell death and improve ischemic stroke outcomes in mice.

Authors:  Louise D McCullough; Meaghan Roy-O'Reilly; Yun-Ju Lai; Anthony Patrizz; Yan Xu; Juneyoung Lee; Aleah Holmes; Daniel C Kraushaar; Anjali Chauhan; Lauren H Sansing; Barbara S Stonestreet; Liang Zhu; Julia Kofler; Yow-Pin Lim; Venugopal Reddy Venna
Journal:  J Clin Invest       Date:  2021-09-01       Impact factor: 14.808

3.  Complement C5a is present in CSF of human newborns and is elevated in association with preterm birth.

Authors:  Rozalia Pataky; Forbes A Howie; Guillermina Girardi; James P Boardman
Journal:  J Matern Fetal Neonatal Med       Date:  2016-11-21

4.  Evidence that the EphA2 receptor exacerbates ischemic brain injury.

Authors:  John Thundyil; Silvia Manzanero; Dale Pavlovski; Tanya R Cully; Ker-Zhing Lok; Alexander Widiapradja; Prasad Chunduri; Dong-Gyu Jo; Chie Naruse; Masahide Asano; Bradley S Launikonis; Christopher G Sobey; Mark G Coulthard; Thiruma V Arumugam
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

Review 5.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

6.  Activated complement protein C5a does not affect brain-derived endothelial cell viability and zonula occludens-1 levels following oxygen-glucose deprivation.

Authors:  Aren Khoyetsyan; Rachid Kacimi; Gohar Tsakanova; Anna Boyajyan; Arsen Arakelyan; Midori A Yenari
Journal:  Brain Circ       Date:  2017-03-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.